Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) — Net Asset Momentum
Shijiazhuang Yiling Pharmaceutical Co Ltd (002603) recorded a net asset momentum of 7.6% as of December 2025, with net assets of CN¥10.98 Billion CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See defensive interval ratio of Shijiazhuang Yiling Pharmaceutical Co Lt to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
Shijiazhuang Yiling Pharmaceutical Co Ltd Net Asset Momentum (2008–2025)
This chart tracks Shijiazhuang Yiling Pharmaceutical Co Ltd's year-over-year net asset growth across 18 annual reporting periods from 2008 to 2025. The most recent momentum reading is +7.6%, with net assets of CN¥10.98 Billion CNY as of December 2025. Read total liabilities of Shijiazhuang Yiling Pharmaceutical Co Lt for a breakdown of total debt and financial obligations.
Annual Net Asset History for Shijiazhuang Yiling Pharmaceutical Co Ltd (2008–2025)
The table below shows the complete annual net asset history for Shijiazhuang Yiling Pharmaceutical Co Ltd from 2008 to 2025, covering 18 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see Shijiazhuang Yiling Pharmaceutical Co Lt (002603) market capitalisation.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | CN¥10.98 Billion | CN¥13.67 Billion | CN¥2.69 Billion | ▲ +7.6% |
| 2024 | CN¥10.20 Billion | CN¥13.32 Billion | CN¥3.12 Billion | ▼ -10.8% |
| 2023 | CN¥11.44 Billion | CN¥16.98 Billion | CN¥5.54 Billion | ▲ +4.6% |
| 2022 | CN¥10.93 Billion | CN¥16.34 Billion | CN¥5.41 Billion | ▲ +20.5% |
| 2021 | CN¥9.07 Billion | CN¥12.90 Billion | CN¥3.83 Billion | ▲ +1.7% |
| 2020 | CN¥8.92 Billion | CN¥11.51 Billion | CN¥2.58 Billion | ▲ +12.2% |
| 2019 | CN¥7.95 Billion | CN¥9.07 Billion | CN¥1.12 Billion | ▲ +5.1% |
| 2018 | CN¥7.56 Billion | CN¥8.56 Billion | CN¥993.56 Million | ▲ +6.4% |
| 2017 | CN¥7.11 Billion | CN¥7.89 Billion | CN¥775.58 Million | ▲ +33.4% |
| 2016 | CN¥5.33 Billion | CN¥6.26 Billion | CN¥925.04 Million | ▲ +10.5% |
| 2015 | CN¥4.83 Billion | CN¥5.71 Billion | CN¥879.56 Million | ▲ +9.3% |
| 2014 | CN¥4.42 Billion | CN¥5.09 Billion | CN¥671.19 Million | ▲ +3.7% |
| 2013 | CN¥4.26 Billion | CN¥4.66 Billion | CN¥399.69 Million | ▲ +10.8% |
| 2012 | CN¥3.84 Billion | CN¥4.17 Billion | CN¥320.75 Million | ▲ +3.9% |
| 2011 | CN¥3.70 Billion | CN¥4.23 Billion | CN¥523.78 Million | ▲ +239.3% |
| 2010 | CN¥1.09 Billion | CN¥1.77 Billion | CN¥680.08 Million | ▲ +38.0% |
| 2009 | CN¥790.55 Million | CN¥1.51 Billion | CN¥718.89 Million | ▲ +63.3% |
| 2008 | CN¥484.03 Million | CN¥831.91 Million | CN¥347.88 Million | — |